Francesco d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark provides an overview of the LUMIERE clinical trial of alisertib (MLN8237), an Aurora A kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. When compared to standard of care, such as romidepsin, pralatrexate and gemcitabine, there was no difference in terms of efficacy. However, Dr D’Amore discusses that this clinical was a great achievement in a field of rare diseases such as T-cell lymphomas.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates